Ellsworth Advisors LLC acquired a new position in Agilon Health, Inc. (NYSE:AGL – Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 10,161 shares of the company’s stock, valued at approximately $809,000.
A number of other hedge funds and other institutional investors also recently made changes to their positions in AGL. State Street Corp acquired a new stake in Agilon Health in the 2nd quarter valued at about $30,024,000. Alpine Global Management LLC acquired a new position in shares of Agilon Health during the fourth quarter valued at $84,000. Rubicon Founders LLC bought a new position in Agilon Health in the second quarter valued at about $11,290,448. Tidal Investments LLC bought a new position in Agilon Health in the second quarter valued at about $1,405,000. Finally, Great Lakes Advisors LLC bought a new position in Agilon Health in the second quarter valued at about $702,000.
Agilon Health Price Performance
Shares of NYSE AGL opened at $88.09 on Friday. The firm has a market cap of $1.48 billion, a PE ratio of -6.17 and a beta of 2.98. The company has a current ratio of 1.08, a quick ratio of 1.08 and a debt-to-equity ratio of 0.07. Agilon Health, Inc. has a 1-year low of $7.48 and a 1-year high of $133.04. The company has a fifty day moving average price of $88.63 and a 200 day moving average price of $81.54.
Agilon Health (NYSE:AGL – Get Free Report) last released its earnings results on Wednesday, August 5th. The company reported $1.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.14 by $0.90. Agilon Health had a negative return on equity of 119.38% and a negative net margin of 3.92%. The firm had revenue of $1.49 billion during the quarter, compared to analysts’ expectations of $1.45 billion. Research analysts predict that Agilon Health, Inc. will post -2.90 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of brokerages have issued reports on AGL. Sanford C. Bernstein raised shares of Agilon Health from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $86.00 to $125.00 in a research note on Tuesday, September 15th. JPMorgan Chase & Co. upped their price objective on Agilon Health from $31.00 to $85.00 and gave the company an “underweight” rating in a report on Monday, August 24th. Barclays set a $111.00 target price on Agilon Health and gave the company an “equal weight” rating in a research note on Thursday, August 6th. Benchmark reiterated a “buy” rating and issued a $140.00 price target (up from $95.00) on shares of Agilon Health in a research report on Thursday, August 6th. Finally, Truist Financial set a $112.00 target price on Agilon Health and gave the stock a “hold” rating in a report on Thursday, August 6th. Six analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $102.25.
Check Out Our Latest Report on Agilon Health
Agilon Health Profile
Agilon Health, Inc is a healthcare company that helps primary care physicians transition from traditional fee-for-service medicine to value-based care. The company primarily works with independent physician practices that serve older adults, particularly Medicare Advantage members, with the goal of improving care coordination, patient outcomes and the overall healthcare experience.
Agilon provides a technology and services platform designed to support population health management. Its offerings include data analytics, clinical and administrative workflows, practice management support, care coordination resources and assistance with payer contracting.
See Also
- Five stocks we like better than Agilon Health
- ASML Can’t Keep Up With AI Demand—Why That’s a Good Thing
- Enovix’s 100,000-Battery Drone Order Sets Up a Test of Its Production Plans
- AMD’s Support Could Help Fermi Stock Overcome Its Biggest Hurdle
- Beyond the GPU: Credo Paves the Next AI Data Superhighway
Want to see what other hedge funds are holding AGL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilon Health, Inc. (NYSE:AGL – Free Report).
Receive News & Ratings for Agilon Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilon Health and related companies with MarketBeat.com's FREE daily email newsletter.
